| Molecular formula | C45H55N9O6 |
|---|
| Molecular weight | 818 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 6918245 |
|---|
What GHRP-2 Is
GHRP-2 is a synthetic peptide compound with the molecular formula C45H55N9O6 and a molecular weight of approximately 818 g/mol. It has no FDA-approved label, meaning no approved indications, dosing, or safety information have been established by regulators for human use. The compound is classified as unapproved and is currently used only in a research context. Its PubChem entry (CID 6918245) documents its chemical structure but does not constitute regulatory approval or clinical guidance.
Trial Footprint
No registered clinical trials for GHRP-2 appear in the dataset reviewed. This indicates either an absence of listed studies at the time of data collection or that any research activity has not been catalogued in the source registry. Without trial data, no conclusions can be drawn about study phase, design, or outcomes.
FAQ
No. GHRP-2 has no FDA-approved label, brand name, or approved indication. It is classified as an unapproved research compound, and no regulatory body has evaluated it for human therapeutic use.
GHRP-2 is a synthetic peptide with the molecular formula C45H55N9O6 and a molecular weight of about 818 g/mol. Its structure is catalogued in PubChem under CID 6918245.
The dataset reviewed shows zero registered clinical trials for GHRP-2. This means there is no available trial data on study phase, design, or reported outcomes for this compound.
No adverse event report data was available for GHRP-2 in the dataset reviewed. Without such data, no pattern of reported reactions can be summarized.
It means the substance has not received regulatory approval for any medical use and lacks an official prescribing label. Any use is confined to research settings rather than approved clinical practice.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-08-03